TG THERAPEUTICS (TGTX) Downgraded by Zacks to NEUTRAL

Zacks Zacks Investment Research downgraded shares of TG THERAPEUTICS (TGTX) from OUTPERFORM to NEUTRAL on January 27, 2014, with a target price of $5.70.

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on TG THERAPEUTICS (TGTX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .

Be the first to comment

Leave a Reply